Notably, GPR65 expression also influences immunotherapy outcomes: in a mouse model of B-cell acute lymphoblastic leukemia, low GPR65 expression conferred resistance to CD19 + CAR T therapy, partly by remodeling tumor–macrophage interactions. Here, GPR65 is linked to B-cell acute lymphoblastic leukemia.